On September 2, Tempus AI rose 5.78% in regular trading, trading at $65.73/share, with turnover of $46.70 million. The rally was driven by back-to-back bullish signals from two major investment banks.

Cantor Fitzgerald initiated coverage on Tempus AI with an \"Overweight\" rating and an $80 price target — the highest among all sell-side analysts. One day earlier, Piper Sandler upgraded the stock from \"Neutral\" to \"Overweight,\" significantly raising its price target from $56 to $76. According to FactSet, the current analyst consensus rating stands at \"Overweight\" with a mean target price of $65.79.

The upgrades helped offset recent headwinds, including CEO Eric Lefkofsky's continued insider selling of approximately 250,000 shares through a 10b5-1 plan, as well as ARK Invest's reduction of over 250,000 shares. On the fundamental side, the company reported Q2 revenue of $382.5 million, beating estimates of $379.7 million, and raised full-year revenue guidance to $1.60–$1.61 billion. The company also recently secured FDA clearance for its AI-enabled pulmonary hypertension detection device.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)